Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 9/20 | 0.57 |
| ▸ | PGR | P06401 | 2/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13804526 | 1.00 | CYP19A1 (0.57) | CYP19A1PGRAKR1C3MAPK1TSHR | |
| SCHEMBL4587874 | 0.84 | CYP19A1 (0.47) | CYP19A1PGRAKR1C3MAPK1TSHR | |
| SCHEMBL13125426 | 0.82 | CYP19A1 (0.64) | CYP19A1PGRMAPK1TSHRHSD17B10 | |
| SCHEMBL10599486 | 0.82 | CYP19A1 (0.64) | CYP19A1PGRMAPK1TSHRHSD17B10 | |
| SCHEMBL908121 | 0.82 | CYP19A1 (0.64) | CYP19A1PGRMAPK1TSHRHSD17B10 | |
| SCHEMBL907789 | 0.82 | CYP19A1 (0.64) | CYP19A1PGRMAPK1TSHRHSD17B10 | |
| SCHEMBL12902155 | 0.82 | CYP19A1 (0.64) | CYP19A1PGRMAPK1TSHRHSD17B10 | |
| SCHEMBL14535132 | 0.82 | CYP19A1 (0.64) | CYP19A1PGRMAPK1TSHRHSD17B10 | |
| SCHEMBL6843517 | 0.81 | CYP19A1 (0.65) | CYP19A1PGRMAPK1TSHRHSD17B10 | |
| SCHEMBL14946858 | 0.81 | CYP19A1 (0.65) | CYP19A1PGRMAPK1TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231692-A1 | METHOD FOR THE AROMATIZATION OF 19-NOR-ANDROST-4-EN-3-ONES INTO ESTRA-1,3,5(10)-TRIENES | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009074313-A1 | METHOD FOR THE AROMATIZATION OF 19-NOR-ANDROST-4-EN-3-ONES INTO ESTRA-1,3,5(10)-TRIENES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-18 | — | — | WO | disclosed |
| US-20090156843-A1 | PROCESS FOR AROMATIZING 19-NORANDROST-4-EN-3-ONES TO ESTRA-1,3,5(10)-TRIENES | BAYER SCHERING PHARMA AG (DE) | 2009-06-18 | — | — | US | disclosed |
| EP-2070942-A1 | Method for aromatising 19-nor-androst-4-en-3-ones to estra-1,3,5(10)-trienes | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156843-A1 | PROCESS FOR AROMATIZING 19-NORANDROST-4-EN-3-ONES TO ESTRA-1,3,5(10)-TRIENES | CYP19A1, HSD17B11, NR5A1 | CYP19A1 1/4885PGR 164/4885AKR1C3 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.